CV Sciences, Inc.
CVSI · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.01 | 0.01 | 0.02 |
| FCF Yield | -14.81% | 41.40% | -42.15% | -58.12% |
| EV / EBITDA | -3.37 | 1.19 | -0.95 | -0.89 |
| Quality | ||||
| ROIC | -84.67% | 16.33% | -893.44% | -405.20% |
| Gross Margin | 45.64% | 44.27% | 34.25% | 42.98% |
| Cash Conversion Ratio | 0.36 | 0.73 | 0.23 | 0.48 |
| Growth | ||||
| Revenue 3-Year CAGR | -1.04% | -7.23% | -12.79% | -27.99% |
| Free Cash Flow Growth | -139.01% | 219.52% | 74.93% | 10.02% |
| Safety | ||||
| Net Debt / EBITDA | -0.18 | -0.23 | -0.16 | 0.03 |
| Interest Coverage | -10.33 | 0.00 | -4.44 | -131.76 |
| Efficiency | ||||
| Inventory Turnover | 1.74 | 1.58 | 1.62 | 1.33 |
| Cash Conversion Cycle | 139.20 | 146.76 | 163.84 | 228.73 |